ICLUSIG® (ponatinib) COULD BE THE RIGHT STEP IN TREATING YOUR CML OR Ph+ ALL

ICLUSIG is a tyrosine kinase inhibitor (TKI) that may help control your CML or Ph+ ALL

ICLUSIG is approved for newly diagnosed adults with Ph+ ALL, in combination with chemotherapy.

Is ICLUSIG right for you?

ICLUSIG is a prescription medicine used to treat adults who have:

  • Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
    • in combination with chemotherapy in newly diagnosed Ph+ ALL*
    • alone in adults with Ph+ ALL who cannot receive any other kinase inhibitor medicines or who have a specific type of abnormal gene (T315I-positive) Ph+ ALL
  • Chronic Myeloid Leukemia (CML)    
    • chronic phase CML who did not tolerate or no longer benefit from treatment with at least 2 prior kinase inhibitor medicines
    • accelerated phase or blast phase CML who cannot receive any other kinase inhibitor medicines
    • a specific type of abnormal gene (T315I-positive) chronic phase, accelerated phase, or blast phase CML 

ICLUSIG is not for use to treat people with newly diagnosed chronic phase CML. 

It is not known if ICLUSIG is safe and effective in children.

*ICLUSIG in combination with chemotherapy in newly diagnosed adult patients with Ph+ ALL was approved based on patient responses at 3 months of therapy. There is an ongoing study to confirm results.

Discover how ICLUSIG may help adults with CML and Ph+ ALL

ICLUSIG in CML

""

Learn more about treatment benefits and risks from clinical studies.

ICLUSIG in Ph+ ALL

""

See the clinical study results in newly diagnosed adults, and adults whose TKIs stopped working.

How can mutations impact your treatment?

BCR-ABL.

If you see your BCR-ABL1 levels rising, a mutation may be to blame.

Meet real patients with CP-CML sharing their stories about treatment with ICLUSIG

"My family has noticed a difference now that I'm taking ICLUSIG."

Watch Matt's story 

"ICLUSIG means that I can continue to enjoy life's little pleasures."

Watch Mike's story 

Disclaimer: These videos feature real patients sharing their experiences living with CP-CML and being treated with ICLUSIG. The information in these videos is based on their experiences at the time of recording. Given the nature of CP-CML experiences may change over time. These are Mike's and Matt’s experiences while taking ICLUSIG and yours may be different.

Explore treatment resources

Access guides, brochures, and education materials for ICLUSIG.

You could pay as little as $0 per prescription*

Learn how the Takeda Oncology Co-Pay Assistance Program may help.

*Terms and conditions apply.

*By enrolling in the Takeda Oncology Co-Pay Assistance Program (the “Program”), you acknowledge that you currently meet the eligibility criteria and will comply with the following terms and conditions:

You must be at least 18 years old, a resident of the United States or a US Territory, and have commercial (private) prescription insurance that does not cover the entire cost of the medication. The Program is not valid for patients whose prescription claims are eligible to be reimbursed, in whole or in part, by any state or federal government program, including, but not limited to, Medicare, Medicare Advantage, Medigap, Medicaid, Department of Defense (DoD), Veterans Affairs (VA), TRICARE, Puerto Rico Government Insurance, or any state patient or pharmaceutical assistance program. Patients who become eligible for or start using government insurance will no longer be eligible for the Program. The Program is not valid if the entire cost of your prescription is reimbursable by a private insurance plan or other private health or pharmacy benefit programs. You are responsible for reporting receipt of Program assistance to any insurer, health plan, or other third party who pays for or reimburses any part of the medication cost, as may be required.

You agree that you will not submit the cost of any portion of the product dispensed pursuant to this Program to a federal or state healthcare program (including, but not limited to, Medicare, Medicare Advantage, Medicaid, TRICARE, VA, DOD, etc.), for purposes of counting it toward your out-of-pocket expenses, and to notify Takeda Oncology Here2Assist® if you become eligible for a federal or state healthcare program. This Program is not conditioned on any past, present or future purchase of any Takeda product, including refills. This Program is valid for 12 months, and your co-pay card may be renewed every 12 months, subject to continued eligibility. This offer is not valid with any other program, discount, or offer involving your prescribed Takeda Oncology medication. This offer may be rescinded, revoked, or amended without notice. No reproductions. This offer is void where prohibited by law, taxed, or restricted. Limit one offer per purchase. No income requirements or membership fees. This Program is not health insurance. Cash value of 1/100 of 1¢. For questions about this offer, please contact the Takeda Oncology Co-Pay Assistance Program, a patient support service of Takeda Oncology Here2Assist, at 1-844-817-6468, Option 2, Monday-Friday, 8 AM-8 PM ET.